Publications by authors named "L Casciola-Rosen"

Objectives: CD209L and its homologous protein CD209 act as alternative entry receptors for the SARS-CoV-2 virus and are highly expressed in the virally targeted tissues. We tested for the presence and clinical features of autoantibodies targeting these receptors and compared these with autoantibodies known to be associated with COVID-19.

Methods: Using banked samples ( = 118) from Johns Hopkins patients hospitalised with COVID-19, we defined autoantibodies against CD209 and CD209L by enzyme-linked immunosorbent assay (ELISA).

View Article and Find Full Text PDF

Background: Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A subset of SSc patients harbor autoantibodies against the M2 mitochondrial antigen (AMA).

View Article and Find Full Text PDF

Objectives: Anti-TIF1γ autoantibodies are associated with malignancy in adult-onset idiopathic inflammatory myopathy (IIM) and this risk is attenuated if patients are also positive for anti-specificity protein 4 (Sp4) or anti-cell division cycle apoptosis regulator protein 1 (CCAR1). In anti-TIF1γ positive US dermatomyositis (DM) patients, anti-Sp4 and anti-CCAR1 autoantibody frequencies are reported as 32% and 43% in adults and 9% and 19% in juveniles, respectively. This study aims to identify the frequency of anti-Sp4 and anti-CCAR1 in adult and juvenile UK anti-TIF1ƴ-positive myositis populations and report clinical associations.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to analyze the frequency and relationship of two autoantibodies, anti-CCAR1 and anti-Sp4, in adult dermatomyositis (DM) patients and their link to cancer.
  • - Researchers studied data from 305 anti-TIF1γ-positive DM patients at Johns Hopkins and Stanford, discovering that about one-third were positive for each antibody, with 20% positive for both.
  • - Results indicated that those without anti-Sp4 or anti-CCAR1 had a stronger association with cancer, whereas patients positive for either antibody had a lower risk; nevertheless, half of the patients were negative for both and may need closer cancer monitoring.
View Article and Find Full Text PDF